Pharmacy - Pharmacoeconomics News & Articles

141 When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?: A Systematic Review of NICE Guidance PharmacoEconomics, February 20, 2013    Evidence Based Medicine    Review Article    Clinical Guideline

142 Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy Full Text Haematologica, February 19, 2013    Clinical Article

143 Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis The Journal of Allergy and Clinical Immunology, February 19, 2013    Clinical Article

144 Cost-Effectiveness Acceptability Curves Revisited PharmacoEconomics, February 19, 2013    Review Article

145 Acknowledging Patient Heterogeneity in Economic Evaluation: A Systematic Literature Review PharmacoEconomics, February 19, 2013    Review Article

146 Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation Full Text Health Policy, February 19, 2013    Review Article

147 Low cost, disposable biosensors allow detection of antibodies with results equivalent to ELISA in 15min Journal of Immunological Methods, February 18, 2013    Review Article

148 Cost of hospitalizing children with invasive pneumococcal pneumonia Vaccine , February 14, 2013    Review Article

149 Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model Vaccine , February 14, 2013    Review Article

150 A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination PharmacoEconomics, February 14, 2013    Evidence Based Medicine    Review Article

151 Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling: Development and Validation of a Micro-Simulation Approach PharmacoEconomics, February 14, 2013    Review Article    Clinical Guideline

152 Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled Trials PharmacoEconomics, February 14, 2013    Review Article

153 High cost, renal complications in diabetes management Full Text Drug Topics, February 13, 2013    Review Article

154 Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model Vaccine , February 13, 2013    Review Article

155 Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B PharmacoEconomics, February 12, 2013    Review Article

156 The Humanistic and Economic Burden of Systemic Lupus Erythematosus PharmacoEconomics, February 12, 2013    Review Article

157 Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study Annals of Pharmacotherapy, February 11, 2013    Review Article

158 Dalfampridine Prior Authorization Program: A Cohort Study Full Text Journal of Managed Care Pharmacy, February 8, 2013    Review Article

159 Assessing the Cost-Benefit Effect of a Plasmodium falciparum Drug Resistance Mutation on Parasite Growth In Vitro Antimicrobial Agents and Chemotherapy, February 8, 2013    Review Article

160 Robotic and open radical prostatectomy in the public health sector: cost comparison ANZ Journal of Surgery, February 7, 2013    Review Article

1 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement Clinical Therapeutics, April 18, 2013    Review Article

2 The Economic Burden of Treatment-Resistant Depression Clinical Therapeutics, April 19, 2013

3 Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact Journal of Clinical Pharmacy and Therapeutics, April 10, 2013    Review Article

4 Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US Annals of Pharmacotherapy, April 22, 2013    Review Article

5 Role of the Pharmacist in Achieving Performance Measures to Improve the Prevention and Treatment of Venous Thromboembolism Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 9, 2013

6 A systematic review and meta-analysis of pharmacist-led fee-for-services medication review British Journal of Clinical Pharmacology, April 24, 2013    Evidence Based Medicine    Review Article

7 Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation Clinical Cardiology, March 18, 2013    Free full text

8 Cost-effectiveness of deep brain stimulation in patients with Parkinsons disease Movement Disorders, April 29, 2013

9 Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany Clinical Research in Cardiology, March 27, 2013

10 Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer Annals of Oncology, March 26, 2013

11 The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, April 29, 2013

12 Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial Vaccine , March 20, 2013

13 Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013 American Journal of Health-System Pharmacy, March 13, 2013    Review Article

14 Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies Bone Marrow Transplantation, April 16, 2013

15 Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations- A simulation of comparative cost-effectiveness British Journal of Cancer, April 15, 2013    Review Article

16 Systematic Review and Quality Assessment of Cost-Effectiveness Analysis of Pharmaceutical Therapies for Advanced Colorectal Cancer Annals of Pharmacotherapy, April 8, 2013    Evidence Based Medicine    Review Article

17 Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer Colorectal Disease, April 2, 2013

18 The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions Multiple Sclerosis Journal, April 22, 2009

19 Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom Clinical Therapeutics, March 26, 2013

20 Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting Cardiovascular Drugs and Therapy, March 28, 2013